Valuation: STAAR Surgical Company

Capitalization 806M 681M 622M 596M 1.1B 73.04B 1.14B 7.26B 2.87B 35.23B 3.02B 2.96B 124B P/E ratio 2025 *
-14.3x
P/E ratio 2026 * 810x
Enterprise value 669M 565M 516M 494M 913M 60.6B 947M 6.02B 2.38B 29.23B 2.51B 2.46B 103B EV / Sales 2025 *
2.6x
EV / Sales 2026 * 2x
Free-Float
99.47%
Yield 2025 *
-
Yield 2026 * -
1 day+0.62%
1 week-6.36%
Current month-14.51%
1 month-22.75%
3 months-38.87%
6 months-42.90%
Current year-29.84%
1 week 15.58
Extreme 15.585
17.24
1 month 15.58
Extreme 15.585
21.27
Current year 15.58
Extreme 15.585
24.26
1 year 14.69
Extreme 14.69
30.81
3 years 13.5
Extreme 13.5
73.13
5 years 13.5
Extreme 13.5
163.08
10 years 4.98
Extreme 4.98
163.08
Manager TitleAgeSince
Chief Executive Officer 68 31/01/2026
Chief Executive Officer 50 31/01/2026
Chief Tech/Sci/R&D Officer 64 30/09/2017
Director TitleAgeSince
Director/Board Member 43 30/11/2023
Director/Board Member 55 11/03/2024
Director/Board Member 62 11/03/2024
Change 5d. change 1-year change 3-years change Capi.($)
+0.62%-6.36%+5.54%-76.94% 806M
-0.37%-0.02%-14.05%+5.17% 195B
-3.10%-4.94%+3.88%+13.69% 124B
-0.24%-0.01%+48.36%+122.91% 70.03B
-0.97%-4.52%+42.73%+102.65% 60.35B
+0.85%+3.32%-21.09%-27.46% 50.51B
+3.61%+1.92% - - 38.41B
+0.59%+3.33%-20.93%-38.63% 27.11B
-1.18%+0.30%+11.89%+29.39% 24.07B
-0.26%-4.40%-18.19%-48.38% 19.64B
Average -0.04%-1.28%+4.24%+9.16% 60.97B
Weighted average by Cap. -0.59%-0.87%+3.51%+25.84%

Financials

2025 *2026 *
Net sales 258M 218M 199M 190M 352M 23.34B 365M 2.32B 919M 11.26B 966M 946M 39.56B 311M 263M 240M 230M 424M 28.17B 440M 2.8B 1.11B 13.59B 1.17B 1.14B 47.73B
Net income -52.83M -44.67M -40.79M -39.05M -72.14M -4.79B -74.79M -476M -188M -2.31B -198M -194M -8.11B 931K 787K 719K 688K 1.27M 84.4M 1.32M 8.39M 3.32M 40.71M 3.49M 3.42M 143M
Net Debt -137M -116M -106M -101M -187M -12.44B -194M -1.24B -490M -6B -515M -504M -21.08B -185M -157M -143M -137M -253M -16.81B -263M -1.67B -662M -8.11B -696M -681M -28.49B
Logo STAAR Surgical Company
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Employees
1,157
Date Price Change Volume
17/02/26 16.20 $ +0.62% 1,968,329
13/02/26 16.10 $ -2.37% 805,650
12/02/26 16.49 $ -4.41% 1,001,532
11/02/26 17.25 $ -0.29% 1,326,588
10/02/26 17.30 $ -0.63% 944,198
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
16.20USD
Average target price
22.72USD
Spread / Average Target
+40.28%

Quarterly revenue - Rate of surprise